PSI is the global leader in radioligand research, running 50% of the industry’s pivotal Phase 2 and 3 radiopharm studies. We work with more than 1,000 experienced sites worldwide and have a dedicated regulatory team that continues to maintain and grow our knowledge to speed up country and site activation.

Clinical trial sponsors working in oncology, hematology, IBD, infectious diseases, multiple sclerosis, and many rare diseases around the world rely on PSI’s guidance and experience, knowing we’re specialized and committed to delivering some of the most complex clinical projects in the industry.